Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Share-based Compensation (2016 - 2025)

Immucell's Share-based Compensation history spans 16 years, with the latest figure at $103781.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 50.71% year-over-year to $103781.0; the TTM value through Dec 2025 reached $295871.0, down 9.12%, while the annual FY2025 figure was $295871.0, 9.12% down from the prior year.
  • Share-based Compensation reached $103781.0 in Q4 2025 per ICCC's latest filing, up from $73161.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $103781.0 in Q4 2025 to a low of $23265.0 in Q2 2021.
  • Average Share-based Compensation over 5 years is $70042.3, with a median of $71012.0 recorded in 2024.
  • Peak YoY movement for Share-based Compensation: crashed 58.92% in 2021, then skyrocketed 164.93% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $40931.0 in 2021, then soared by 59.77% to $65395.0 in 2022, then skyrocketed by 53.92% to $100659.0 in 2023, then plummeted by 31.59% to $68863.0 in 2024, then soared by 50.71% to $103781.0 in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Share-based Compensation are $103781.0 (Q4 2025), $73161.0 (Q3 2025), and $66714.0 (Q2 2025).